Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Clin Cancer Res. 2019 Nov 12;26(3):726–737. doi: 10.1158/1078-0432.CCR-19-1800

Figure 1. The cryptic fusion CBFA2T3-GLIS2 is most prevalent in patients less than 3 years old and is associated with poor outcomes.

Figure 1.

A) Representation of the most common breakpoint in in pediatric AML (Zhou et al. 2015) and B) resulting in the CBA2T3-GLIS2 fusion transcript. C) Frequency of CBFA2T3-GLIS2 occurrence by age group. D) Oncoprint with CBFA2T3-GLIS2 cohort. Columns are patients and genetic abnormalities are rows. *One patient (purple) was identified as inv(16) through FISH, though no RNA-seq or karyotype evidence was detected. E) Kaplan-Meier estimates for CBFA2T3-GLIS2 AML compared to fusion-negative cohorts.